Tarceva Price Will Be In Bounds, OSI Says: Above Iressa, Below Gleevec

Genentech/OSI will price the EGFR inhibitor Tarceva between AstraZeneca's Iressa and Novartis' Gleevec, OSI CEO Colin Goddard, PhD, said